PL2964233T3 - Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych - Google Patents

Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych

Info

Publication number
PL2964233T3
PL2964233T3 PL13878203T PL13878203T PL2964233T3 PL 2964233 T3 PL2964233 T3 PL 2964233T3 PL 13878203 T PL13878203 T PL 13878203T PL 13878203 T PL13878203 T PL 13878203T PL 2964233 T3 PL2964233 T3 PL 2964233T3
Authority
PL
Poland
Prior art keywords
treating
reducing
methods
ischemic events
preventing ischemic
Prior art date
Application number
PL13878203T
Other languages
English (en)
Polish (pl)
Inventor
Clive Arthur Arculus-Meanwell
Simona Skerjanec
Jayne Prats
David J. Schneider
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL2964233T3 publication Critical patent/PL2964233T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL13878203T 2013-03-09 2013-05-29 Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych PL2964233T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US201361815735P 2013-04-25 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP13878203.2A EP2964233B1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Publications (1)

Publication Number Publication Date
PL2964233T3 true PL2964233T3 (pl) 2022-04-25

Family

ID=51537409

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13878203T PL2964233T3 (pl) 2013-03-09 2013-05-29 Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych

Country Status (10)

Country Link
EP (2) EP3978002A1 (enExample)
JP (3) JP6247708B2 (enExample)
CN (2) CN106102750A (enExample)
AU (1) AU2013381855B2 (enExample)
BR (1) BR112015022070B1 (enExample)
CA (1) CA2904523C (enExample)
EA (1) EA034550B1 (enExample)
ES (1) ES2904256T3 (enExample)
PL (1) PL2964233T3 (enExample)
WO (1) WO2014143107A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978002A1 (en) * 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406649T2 (de) 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
CN102271685A (zh) * 2008-12-30 2011-12-07 斯若姆博洛捷克有限公司 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
UY32711A (es) * 2009-06-16 2011-01-31 Cardoz Ab Nueva forma cristalina de pemirolast
EP2498731B1 (en) * 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
EP3978002A1 (en) * 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events

Also Published As

Publication number Publication date
CA2904523A1 (en) 2014-09-18
JP2016510738A (ja) 2016-04-11
EA201591683A1 (ru) 2016-08-31
EP2964233B1 (en) 2021-12-15
ES2904256T3 (es) 2022-04-04
JP6247708B2 (ja) 2017-12-13
WO2014143107A1 (en) 2014-09-18
AU2013381855B2 (en) 2018-08-02
JP2019178177A (ja) 2019-10-17
EP2964233A1 (en) 2016-01-13
CN106102750A (zh) 2016-11-09
BR112015022070B1 (pt) 2022-01-18
EA034550B1 (ru) 2020-02-19
JP6840197B2 (ja) 2021-03-10
AU2013381855A1 (en) 2015-10-22
BR112015022070A2 (pt) 2017-07-18
CN115120606A (zh) 2022-09-30
EP3978002A1 (en) 2022-04-06
EP2964233A4 (en) 2016-10-19
CA2904523C (en) 2024-01-09
JP2018002739A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
IL291723A (en) Methods and devices for skin tightening
IL267681A (en) Selective grp94 inhibitors and their uses
IL259570A (en) Combined therapy and their uses and methods
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
EP2968878A4 (en) DEVICES AND PROCEDURES FOR EXCLUDING THE LEFT FORWARD ANNEX
GB2512988B (en) Dishwasher and method of controlling the same
GB201314917D0 (en) Treated Tobacco and processes for preparing the same, Devices including the same and uses thereof
EP3000200A4 (en) SECURE AUTHORIZATION SYSTEMS AND METHOD
GB201518981D0 (en) Apertured nonwoven materials and methods for forming the same
RS67779B1 (sr) Farmaceutska kompozicija, postupci za lečenje i njihova primena
EP2967978A4 (en) DEVICES, SYSTEMS AND METHOD FOR COOLING THE SKIN
GB201316673D0 (en) Account association systems and methods
GB201402336D0 (en) Dishwasher and method of controlling the same
GB2512987B (en) Dishwasher and method of controlling the same
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
GB201305414D0 (en) Method and composition
SG11201505342QA (en) Valve arrangement and method of operating the same
EP3074084A4 (en) Anchor elements, medical devices including one or more anchor elements and related assemblies and methods
SG11201506389YA (en) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
SG11201407288YA (en) Post-installed anchor, installation thereof and post-installed anchor system
EP3046438A4 (en) Fastening devices and methods
SG11201600119PA (en) Compound and methods for treating long qt syndrome
EP3089622A4 (en) Uni-directional rigidifier and method